Don't Have a Stroke Over Merck's Heart Drug

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

If you're going to invest in the high-risk, high-reward stakes of heart drugs, you've got to be ready for the crashes. Merck's (NYSE: MRK  ) investors found that out the hard way yesterday, when its shares fell nearly 7% after the company announced that one of its most promising pipeline drugs, vorapaxar, might be a dud.

On the recommendation of the Data and Safety Monitoring Board overseeing the two clinical studies that Merck is conducting with vorapaxar, one of them -- codenamed Tracer -- is being stopped, and another trial called TRA-2P will be scaled back to exclude patients who have previously had a stroke.

Merck didn't say exactly why the trials were being stopped, but many people -- this Fool included -- think excessive bleeding is the likely culprit. Bleeding is often a problem with these anticlotting agents because it's hard to hit the small window where you keep a clot from forming but don't go too far and cause bleeding.

Even if a reduction in heart attacks by vorapaxar makes up for the increased bleeding, doctors might not prescribe it. Eli Lilly's (NYSE: LLY  ) Effient has had a horrible time competing with Bristol-Myers Squibb (NYSE: BMY  ) and sanofi-aventis' (NYSE: SNY  ) Plavix, likely because of increased bleeding seen in clinical trials.

The knockdown yesterday was well deserved. Merck -- and Schering-Plough, before Merck bought it -- spent a lot of money on vorapaxar in hopes of it becoming a multibillion-dollar drug. That seems unlikely at this point.

But the loss isn't a complete knockout for Merck, either. Investing in heart drugs, which require large clinical trials, may be risky, but Merck has a decent pipeline of drugs. If it can get a hit, especially for a drug such as odanacatib in the large osteoporosis market, Merck's shares could be headed in the other direction.

Welcome to pharma investing. It isn't just about the dividend.

To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 14, 2011, at 3:37 PM, langco1 wrote:

    merck stock is now a great buy especially when you add in the 4% dividend....

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1423367, ~/Articles/ArticleHandler.aspx, 10/22/2016 12:44:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 15 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:01 PM
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****